MREO

Mereo BioPharma GroupC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$0.45

+32.6% vs current

Most likely

Base case

45%

Probability

Target price

$0.24

-29.3% vs current

B-

Bear case

30%

Probability

Target price

$0.12

-64.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

This remains a cautious post-earnings monitoring view rather than a bullish turn. The May 12, 2026 earnings release/8-K confirmed unchanged runway guidance and preserved the same three forward hooks, but it did not add definitive regulatory feedback or a signed alvelestat partnership. Immediate market reaction was only modestly constructive: MREO closed at $0.243 on May 11, $0.246 on May 12, and $0.2595 on May 13. No trustworthy post-print analyst revision packet was available, so the absence of revisions should not be treated as positive evidence. With low coverage, thin trusted news flow, and a negative deterministic prior despite a meaningful thesis-change score, the update improves monitoring value more than conviction.

RankAlpha Sentiment Codex - 2026-05-14

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-09-30eventSetrusumab regulatory feedback after Phase 3 data re-analysisHigh impact

Management said further analyses from the Orbit and Cosmic Phase 3 studies are complete, regulatory interactions on a possible pediatric path forward have been initiated, and updates will come only after definitive feedback; this remains the clearest thesis-changing event after the missed primary fracture-rate endpoints [#8-K-2026-05-12].

2026-12-31catalystAlvelestat partnership as prerequisite to Phase 3 startHigh impact

Mereo said it is actively engaged with potential partners for alvelestat, expects a single global Phase 3 design could support U.S. and European submissions, and believes study initiation could occur within six months of closing a partnership transaction; until a deal is signed this remains a monitored but unproven second value driver [#8-K-2026-05-12].

2027-06-30catalystRunway durability versus financing overhangHigh impact

Cash and cash equivalents were $36.2 million at March 31, 2026 versus $41.0 million at December 31, 2025, and management kept guidance that cash should fund operations into mid-2027 excluding any business-development payments; holding that runway while advancing milestones would ease dilution fears, while slippage would likely revive financing pressure [#8-K-2026-05-12] [#10-K-2026-03-19].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology